Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Apr 04, 2022 9:59am EDT

SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences

Mar 29, 2022 7:00am EDT

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 24, 2022 8:30am EDT

SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

Mar 08, 2022 8:30am EST

SCYNEXIS Named to Fast Company’s 2022 List of the World’s Most Innovative Companies

Mar 04, 2022 5:00pm EST

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 02, 2022 8:30am EST

SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

Feb 10, 2022 7:36am EST

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

Feb 03, 2022 4:15pm EST

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 06, 2022 1:03pm EST

SCYNEXIS to Participate in Upcoming January Investor Conferences

Dec 22, 2021 8:30am EST

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 32
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2023 SCYNEXIS, Inc. All Rights Reserved.